Daniel Barber
2022
In 2022, Daniel Barber earned a total compensation of $1.3M as Chief Executive Officer at Aquestive Therapeutics, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $355,547 |
|---|---|
| Option Awards | $401,253 |
| Salary | $541,591 |
| Other | $28,207 |
| Total | $1,326,598 |
Barber received $541.6K in salary, accounting for 41% of the total pay in 2022.
Barber also received $355.5K in non-equity incentive plan, $401.3K in option awards and $28.2K in other compensation.
Rankings
In 2022, Daniel Barber's compensation ranked 2,457th out of 5,538 executives tracked by ExecPay. In other words, Barber earned more than 55.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,457 out of 5,538 | 56th |
Division Manufacturing | 1,344 out of 3,000 | 55th |
Major group Chemicals And Allied Products | 606 out of 1,350 | 55th |
Industry group Drugs | 560 out of 1,253 | 55th |
Industry Pharmaceutical Preparations | 399 out of 907 | 56th |
Source: SEC filing on April 26, 2024.
Barber's colleagues
We found one more compensation record of an executive who worked with Daniel Barber at Aquestive Therapeutics in 2022.
2022
Lori Braender
Aquestive Therapeutics
General Counsel
News
Aquestive Therapeutics CEO Daniel Barber's 2023 pay jumps 88% to $2.5M
April 26, 2024
Aquestive Therapeutics CEO Keith Kendall's 2021 pay jumps 59% to $2M
April 29, 2022
Aquestive Therapeutics CFO John Maxwell's 2020 pay jumps 24% to $1.3M
May 5, 2021
Aquestive Therapeutics CEO Keith Kendall's 2019 pay falls 67% to $2.6M
April 29, 2020